Alnylam's CEO Dr. Yvonne Greenstreet discusses HELIOS-B at the European Society of Cardiology Congress in London
- blonca9
- Aug 31, 2024
- 1 min read
Dr. Greenstreet shares her opinion of why she believes the data places vutrisiran in a competitive position to be a first line choice for ATTR-CM, and clarifies market confusion around a data point that was presented yesterday.